Atara Biotherapeutics, Inc. (ATRA) News
Follow Atara Biotherapeutics, Inc. (ATRA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Atara Biotherapeutics Q3 Earnings Preview: EPS Estimate at (0.13) USD
Atara Biotherapeutics is set to report Q3'26 results on October 29. Revenue is estimated at 800.00 thousand USD and EPS at (0.13) USD; the release time is not specified.
EQUITY | Oct 28, 2026, 11:05 AM UTC
M
FDA Accepts Atara Biotherapeutics’ Resubmitted Tab-cel BLA
The FDA assigned a Class 2 review and a PDUFA target action date of March 31, 2027, for tabelecleucel as monotherapy for EBV+ PTLD. Approval would trigger a $31.0 million milestone under Atara’s Pierre Fabre deal.
REGULATION | Oct 14, 2026, 12:05 PM UTC
L
Atara Biotherapeutics, Inc. (ATRA) Partner Resubmits Tab-cel BLA to FDA
Atara said partner Pierre Fabre resubmitted the tabelecleucel (tab-cel) BLA to the FDA with additional patients and longer follow-up from the ALLELE study. Atara expects to provide a revised anticipated PDUFA date when a
REGULATION | Sep 30, 2026, 12:05 PM UTC
L
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi
NEWS | Sep 30, 2026, 12:05 PM UTC
L
Atara director Brian N. Cherry buys $999,993 in common stock
Atara Biotherapeutics director Brian N. Cherry purchased 104,166 shares of common stock at $9.60 per share for $999,993. He directly owns 166,486 shares after the transaction.
EQUITY | Sep 04, 2026, 10:32 PM UTC